Generic placeholder image

Current Drug Discovery Technologies

Editor-in-Chief

ISSN (Print): 1570-1638
ISSN (Online): 1875-6220

Development of a Novel Malarial Vaccine Design: A Hypothetical Approach

Author(s): C. Subathra Devi, Priyanka Verma, Saumya Srivastava, Pranali Ravikumar, Vishal Kalwani, Aishwarya Tandon and V. Mohanasrinivasan

Volume 11, Issue 4, 2014

Page: [239 - 242] Pages: 4

DOI: 10.2174/1570163811666141106102325

Price: $65

Abstract

P. falciparum is highly virulent in nature because of its ability to modify the infected host red blood cells, adherence to the vascular endothelium and changes in antigenicity at different stages. Also slow migration time in the dermal and endothelial cells leads to decreased immune response. To overcome the problems, there is a need to design a vaccine which increases the migration time of the parasite, enhances the immune response, enables recognition of surface antigens and causes minimal clinical infection as a side-effect. An ITI-based (Infection-Treatment Immunization) vaccine development strategy is to be adopted to develop this novel vaccine. This will include administration of a liquid solution of purified, non-attenuated sporozoites from an infected female Anopheles mosquito, AS02A adjuvant and chlorate (a metabolic inhibitor of sulfation that decreases the extent of GAG sulfation). To control infection, a drug-cover of artemisinin will be administered as a part of the vaccination strategy along with a specific protease inhibitor MRT12113 which prevents RBC rupture and reinvasion by the parasite. This vaccine will intend to increase the overall migration time of the parasite in blood which is otherwise approximately 30 minutes, resulting in an overall enhanced immune response. It also intends to reduce parasite invasion in cells and their consequent rupture thus preventing the clinical condition-malaria.

Keywords: ITI-based vaccine, malaria, Plasmodium, vaccine.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy